Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M V Bala

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
International Journal of Technology Assessment in Health Care|May 2, 2001
Estimating the Bayesian loss function. A conjoint analysis approachM V Bala, J Mauskopf
Health Economics|March 18, 2000
Are QALYs an appropriate measure for valuing morbidity in acute diseases?M V Bala, G A Zarkin
Pharmacoeconomics|May 27, 1999
Willingness to pay as a measure of health benefitsM V Bala, J A Mauskopf, L L Wood
Journal of Substance Abuse Treatment|March 15, 2000
Estimating the willingness to pay for drug abuse treatment: a pilot studyG A Zarkin, S C Cates, M V Bala
The American Journal of Managed Care|August 5, 1997
The cost-effectiveness of ibutilide versus electrical cardioversion in the conversion of atrial fibrillation and flutter to normal rhythmG A Zarkin, M V Bala, B Calingaert, et al.
The American Journal of Gastroenterology|August 19, 2000
Annual cost of care for Crohn's disease: a payor perspectiveB G Feagan, M G Vreeland, L R Larson, et al.
The American Journal of Cardiology|July 22, 1998
Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adultsT J Hoerger, M V Bala, J W Bray, et al.
Chest|February 12, 2000
Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation techniqueM G Cochrane, M V Bala, K E Downs, et al.
Clinical Pharmacology and Therapeutics|June 13, 2008
The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplaceJ A Sollano, J M Kirsch, M V Bala, et al.
Pharmacoeconomics|August 18, 2000
Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmineA B Hauber, A Gnanasakthy, E H Snyder, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
International Journal of Technology Assessment in Health Care|May 2, 2001
Estimating the Bayesian loss function. A conjoint analysis approachM V Bala, J Mauskopf
Health Economics|March 18, 2000
Are QALYs an appropriate measure for valuing morbidity in acute diseases?M V Bala, G A Zarkin
Pharmacoeconomics|May 27, 1999
Willingness to pay as a measure of health benefitsM V Bala, J A Mauskopf, L L Wood
Journal of Substance Abuse Treatment|March 15, 2000
Estimating the willingness to pay for drug abuse treatment: a pilot studyG A Zarkin, S C Cates, M V Bala
The American Journal of Managed Care|August 5, 1997
The cost-effectiveness of ibutilide versus electrical cardioversion in the conversion of atrial fibrillation and flutter to normal rhythmG A Zarkin, M V Bala, B Calingaert, et al.
The American Journal of Gastroenterology|August 19, 2000
Annual cost of care for Crohn's disease: a payor perspectiveB G Feagan, M G Vreeland, L R Larson, et al.
The American Journal of Cardiology|July 22, 1998
Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adultsT J Hoerger, M V Bala, J W Bray, et al.
Chest|February 12, 2000
Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation techniqueM G Cochrane, M V Bala, K E Downs, et al.
Clinical Pharmacology and Therapeutics|June 13, 2008
The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplaceJ A Sollano, J M Kirsch, M V Bala, et al.
Pharmacoeconomics|August 18, 2000
Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmineA B Hauber, A Gnanasakthy, E H Snyder, et al.
Pageof 2